mesothelioma/vėmimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 109 rezultatus

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naïve pleural mesothelioma. METHODS Eligible patients had a histologic or cytologic diagnosis of

A phase II study of pirarubicin in malignant pleural mesothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The treatment was repeated every 3 to 4 weeks (median

A rare cause of dysphagia: malignant pleural mesothelioma in the posterior mediastinum.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A 69-year-old man presented to the emergency room with dysphagia and vomiting. A computed tomographic scan revealed a posterior mediastinal mass surrounding the lower portion of the esophagus. Endoscopic examination demonstrated narrowing of the lower esophagus without malignant mucosal lesions.

[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND We performed a phase-II-study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i. e., ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A total of 29 previously untreated patients with histologically proven malignant pleural mesothelioma, with an ECOG score of < or = 2 and UICC stage I-II disease, were enrolled between May 1994 and October 1996. On days 1 and 2, 18 x 10(6) IU/day of rIL-2 was administered by continuous intravenous

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m2 on days 1, 3 and 5 every 3 weeks. The second trial

Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Diffuse malignant peritoneal mesotheliomas in children are uncommon, aggressive tumors with a grave prognosis. We herein report the clinical, radiologic, and pathologic findings of a 16-year-old male. The adolescent presented with a history of abdominal pain, nausea and daily, nonbilious, nonbloody

Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE The combination of chemotherapy, surgery, and radiotherapy has improved the prognosis for patients with malignant pleural mesothelioma (MPM). Intensity-modulated radiotherapy (IMRT) has allowed for an increase in dose to the pleural cavity and a reduction in radiation doses to organs at

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Malignant mesothelioma is a tumour which is generally resistant to chemotherapy. While the addition of interferon to chemotherapy improves response rates in some other malignancies, such a combination has not been evaluated in the treatment of mesothelioma. OBJECTIVE To assess the

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To assess the tolerance, toxicity, and antitumoral activity of the weekly combination of cisplatin (CDDP) and interferon alfa-2a (IFNalpha2a) in advanced diffuse malignant mesothelioma (DMM). METHODS Twenty-six patients with DMM (23 pleural and three peritoneal), previously untreated, were

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To describe the initial experience at Dana-Farber Cancer Institute/Brigham and Women's Hospital with intensity-modulated radiation therapy (IMRT) as adjuvant therapy after extrapleural pneumonectomy (EPP) and adjuvant chemotherapy. METHODS The medical records of patients treated with IMRT

Malignant peritoneal mesothelioma presenting with persistent high fever.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Malignant peritoneal mesothelioma (MPM) is a rare tumor that develops in the peritoneum. In this paper, we describe an extremely rare case of MPM metastasizing to the appendix in a 48-year-old female who initially presented with a persistent high fever. The woman reported a slight lower abdominal

Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE Management of malignant pleural mesothelioma (MPM) has been an important clinical issue regardless of the treatment modality employed. We aimed to investigate the efficacy of oxytetracycline (OT), Corynebacterium parvum (CP), and nitrogen mustard (NM) in the management of pleural effusion

Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND From the moment of diagnosis, malignant mesothelioma (MM) decreases health-related quality of life (QOL) in patients and their caregivers. In addition to symptoms of disease, aggressive treatments such as surgery, radiation, and chemotherapy can cause extreme side effects-chemotherapy

Ankstesnis
1
2
3
4
5
6
7
8
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais